Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2021 | Chemoresistance and drug profiling in ALL

Beat C. Bornhauser • 26 Aug 2021
SOHO 2021
Acute Lymphoblastic Leukemia Leukemia Bortezomib Dasatinib Venetoclax

Beat C. Bornhauser, PhD, of the University Children’s Hospital Zurich, Zurich, Switzerland, outlines chemoresistance and the importance of drug profiling in the treatment of acute lymphoblastic leukemia (ALL). Dr Bornhauser discusses the use of functional assays combined with imaging analysis algorithms to specifically evaluate the survival of leukemia cells in response to different drugs and doses. The combination of molecular and functional profiling in the clinical setting may enable the personalization of treatment and therefore improve patient outcomes. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.

Related Videos

1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals